(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are VerifyMe, GDS Holdings Limited, and Rumble.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | VerifyMe (VRME) | 1.45 | 23.93% | 2024-03-12 15:51:55 |
| 2 | GDS Holdings Limited (GDS) | 7.82 | 22% | 2024-03-12 03:49:05 |
| 3 | Rumble (RUM) | 7.90 | 18.26% | 2024-03-12 15:23:20 |
| 4 | Huize Holding Limited (HUIZ) | 0.76 | 15.86% | 2024-03-12 13:13:05 |
| 5 | Oracle (ORCL) | 127.54 | 11.75% | 2024-03-12 15:57:32 |
| 6 | Hutchison China MediTech Limited (HCM) | 16.68 | 11.5% | 2024-03-12 10:41:07 |
| 7 | HighPeak Energy (HPKEW) | 8.90 | 11.25% | 2024-03-12 11:48:10 |
| 8 | Genprex (GNPX) | 4.70 | 10.59% | 2024-03-12 07:06:07 |
| 9 | FibroGen (FGEN) | 1.89 | 10.53% | 2024-03-12 15:12:11 |
| 10 | Greenland Technologies Holding Corporation (GTEC) | 2.77 | 10.36% | 2024-03-12 09:08:05 |
The three biggest losers today are Hycroft Mining Holding Corporation, Identiv, and Southwest Airlines.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Hycroft Mining Holding Corporation (HYMCW) | 0.01 | -20.47% | 2024-03-12 13:42:06 |
| 2 | Identiv (INVE) | 7.12 | -17.5% | 2024-03-12 15:13:11 |
| 3 | Southwest Airlines (LUV) | 28.76 | -14.86% | 2024-03-12 15:56:29 |
| 4 | Funko (FNKO) | 6.21 | -9.48% | 2024-03-11 22:44:06 |
| 5 | Gritstone Oncology (GRTS) | 2.41 | -9.06% | 2024-03-12 07:48:06 |
| 6 | Pacific Biosciences of California (PACB) | 4.01 | -8.86% | 2024-03-12 15:14:10 |
| 7 | iRobot (IRBT) | 9.86 | -7.85% | 2024-03-12 15:13:16 |
| 8 | Forte Biosciences (FBRX) | 0.71 | -6.96% | 2024-03-11 19:08:06 |
| 9 | Future FinTech Group (FTFT) | 0.96 | -6.6% | 2024-03-12 01:10:05 |
| 10 | Xenetic Biosciences (XBIO) | 4.00 | -6.54% | 2024-03-12 12:18:27 |
Winners today
1. VerifyMe (VRME) – 23.93%
VerifyMe, Inc., together with its subsidiary, PeriShip Global, LLC, operates as a technology solutions provider that specializes in products to connect brands with consumers and providing brands with end-to-end logistics management for their products. The company operates through two segments, VerifyMe Solutions and PeriShip Global Solutions. The VerifyMe Solutions segment offers technology solutions to connect brands with consumers allowing brand owners to gather business intelligence while engaging directly with their consumers. Its solutions provide brand protection and supply chain functions, such as counterfeit prevention, traceability, consumer engagement solutions, and authentication for labels, packaging, and products, as well as tamper-proof labels. The PeriShip Global Solutions segment offers predictive analytics for optimizing delivery of time and temperature sensitive perishable products. This segment's products include PeriTrack customer dashboard, an integrated web portal tool gives its customers an in-depth look at their shipping activities based on real-time data. It also provides call center, pre-transit, post-delivery, and weather/traffic services. The company has a strategic partnership with INX International Ink Company. The company was formerly known as LaserLock Technologies, Inc. and changed its name to VerifyMe, Inc. in July 2015. VerifyMe, Inc. was incorporated in 1999 and is headquartered in Lake Mary, Florida.
NASDAQ ended the session with VerifyMe jumping 23.93% to $1.45 on Tuesday, following the last session’s downward trend. NASDAQ jumped 1.54% to $16,265.64, after two sequential sessions in a row of losses, on what was an all-around up trend trading session today.
Earnings Per Share
As for profitability, VerifyMe has a trailing twelve months EPS of $-0.29.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.16%.
More news about VerifyMe.
2. GDS Holdings Limited (GDS) – 22%
GDS Holdings Limited, together with its subsidiaries, develops and operates data centers in the People's Republic of China. The company provides colocation, managed hosting, and managed cloud services, as well as consulting services to the cloud, internet and banking industries. The company serves cloud service providers, Internet companies, financial institutions, telecommunications and IT service providers, and large domestic private sector and multinational corporations. The company has a strategic partnership with GIC Private Limited to develop and operate hyperscale build-to-suit data centers in China. GDS Holdings Limited was founded in 2001 and is headquartered in Shanghai, the People's Republic of China.
NASDAQ ended the session with GDS Holdings Limited jumping 22% to $7.82 on Tuesday while NASDAQ rose 1.54% to $16,265.64.
Earnings Per Share
As for profitability, GDS Holdings Limited has a trailing twelve months EPS of $-1.02.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.49%.
Yearly Top and Bottom Value
GDS Holdings Limited’s stock is valued at $7.82 at 17:32 EST, way under its 52-week high of $20.78 and way above its 52-week low of $5.01.
Sales Growth
GDS Holdings Limited’s sales growth is 4.9% for the current quarter and 5.9% for the next.
More news about GDS Holdings Limited.
3. Rumble (RUM) – 18.26%
Rumble Inc. operates video sharing platforms in the United States, Canada, and internationally. The company operates rumble.com, a platform where users can subscribe to channels to stay in touch with creators, and access video on-demand (VOD) and live content streamed by creators. It also operates locals.com, a subscription platform for creators and subscribers to engage through VOD, podcasts, live chat, polls, and community discussions; and Rumble Advertising Center (RAC), an online advertising management exchange. The company was founded in 2013 and is headquartered in Longboat Key, Florida.
NASDAQ ended the session with Rumble rising 18.26% to $7.90 on Tuesday while NASDAQ jumped 1.54% to $16,265.64.
Earnings Per Share
As for profitability, Rumble has a trailing twelve months EPS of $-0.42.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.68%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 63.7%, now sitting on 80.53M for the twelve trailing months.
Volume
Today’s last reported volume for Rumble is 11269300 which is 86.12% above its average volume of 6054670.
Volatility
Rumble’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.10%, a negative 0.52%, and a positive 5.50%.
Rumble’s highest amplitude of average volatility was 1.32% (last week), 3.41% (last month), and 5.50% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Rumble’s EBITDA is -28.51.
More news about Rumble.
4. Huize Holding Limited (HUIZ) – 15.86%
Huize Holding Limited, together with its subsidiaries, offers insurance brokerage services in the People's Republic of China. It provides life and health insurance products, such as critical illness, illness and disease, and term life and whole life insurance products; and property and casualty insurance products, including travel, individual casualty, and corporate liability insurance products. The company offers its products through internet and mobile internet channels. It also provides technology development and Internet information consulting services; and management, marketing, investment, and financial consulting services. Huize Holding Limited was founded in 2006 and is headquartered in Shenzhen, the People's Republic of China.
NASDAQ ended the session with Huize Holding Limited rising 15.86% to $0.76 on Tuesday, following the last session’s downward trend. NASDAQ rose 1.54% to $16,265.64, after two successive sessions in a row of losses, on what was an all-around positive trend exchanging session today.
Earnings Per Share
As for profitability, Huize Holding Limited has a trailing twelve months EPS of $0.17.
PE Ratio
Huize Holding Limited has a trailing twelve months price to earnings ratio of 4.45. Meaning, the purchaser of the share is investing $4.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.74%.
Yearly Top and Bottom Value
Huize Holding Limited’s stock is valued at $0.76 at 17:32 EST, way under its 52-week high of $2.08 and way higher than its 52-week low of $0.53.
More news about Huize Holding Limited.
5. Oracle (ORCL) – 11.75%
Oracle Corporation offers products and services that address enterprise information technology environments worldwide. Its Oracle cloud software as a service offering include various cloud software applications, including Oracle Fusion cloud enterprise resource planning (ERP), Oracle Fusion cloud enterprise performance management, Oracle Fusion cloud supply chain and manufacturing management, Oracle Fusion cloud human capital management, Oracle Cerner healthcare, Oracle Advertising, and NetSuite applications suite, as well as Oracle Fusion Sales, Service, and Marketing. The company also offers cloud-based industry solutions for various industries; Oracle application licenses; and Oracle license support services. In addition, it provides cloud and license business' infrastructure technologies, such as the Oracle Database and MySQL Database; Java, a software development language; and middleware, including development tools and others. The company's cloud and license business' infrastructure technologies also comprise cloud-based compute, storage, and networking capabilities; and Oracle autonomous database, MySQL HeatWave, Internet-of-Things, digital assistant, and blockchain. Further, it provides hardware products and other hardware-related software offerings, including Oracle engineered systems, enterprise servers, storage solutions, industry-specific hardware, virtualization software, operating systems, management software, and related hardware services; and consulting and customer services. The company markets and sells its cloud, license, hardware, support, and services offerings directly to businesses in various industries, government agencies, and educational institutions, as well as through indirect channels. The company has a collaboration with Amdocs Limited to empower customers on their journey towards cloud and digital adoption. Oracle Corporation was founded in 1977 and is headquartered in Austin, Texas.
NYSE ended the session with Oracle jumping 11.75% to $127.54 on Tuesday while NYSE rose 0.62% to $17,974.06.
Earnings Per Share
As for profitability, Oracle has a trailing twelve months EPS of $3.62.
PE Ratio
Oracle has a trailing twelve months price to earnings ratio of 35.23. Meaning, the purchaser of the share is investing $35.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3367.77%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Oracle’s EBITDA is 7.51.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Oracle’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for Oracle is 46211900 which is 416.52% above its average volume of 8946630.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jan 10, 2024, the estimated forward annual dividend rate is 1.6 and the estimated forward annual dividend yield is 1.43%.
Previous days news about Oracle
- Oracle (orcl) Q3 earnings and revenues beat estimates. According to Zacks on Monday, 11 March, "While Oracle has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
- Oracle (orcl) Q3 earnings: taking a look at key metrics versus estimates. According to Zacks on Monday, 11 March, "For the quarter ended February 2024, Oracle (ORCL Quick QuoteORCL – Free Report) reported revenue of $13.28 billion, up 7.1% over the same period last year. ", "Here is how Oracle performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about Oracle.
6. Hutchison China MediTech Limited (HCM) – 11.5%
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company is developing HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. HUTCHMED (China) Limited has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., and Shanghai Junshi Biosciences Co. Ltd. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
NASDAQ ended the session with Hutchison China MediTech Limited jumping 11.5% to $16.68 on Tuesday, after two sequential sessions in a row of gains. NASDAQ rose 1.54% to $16,265.64, after two consecutive sessions in a row of losses, on what was an all-around up trend exchanging session today.
Earnings Per Share
As for profitability, Hutchison China MediTech Limited has a trailing twelve months EPS of $0.6.
PE Ratio
Hutchison China MediTech Limited has a trailing twelve months price to earnings ratio of 27.8. Meaning, the purchaser of the share is investing $27.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.65%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 36%, now sitting on 838M for the twelve trailing months.
Yearly Top and Bottom Value
Hutchison China MediTech Limited’s stock is valued at $16.68 at 17:32 EST, way under its 52-week high of $20.73 and way above its 52-week low of $10.68.
More news about Hutchison China MediTech Limited.
7. HighPeak Energy (HPKEW) – 11.25%
HighPeak Energy, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, development, and production of oil, natural gas, and natural gas liquids reserves in the Midland Basin in West Texas and Eastern New Mexico. The company was incorporated in 2019 and is headquartered in Fort Worth, Texas.
NASDAQ ended the session with HighPeak Energy jumping 11.25% to $8.90 on Tuesday, following the last session’s downward trend. NASDAQ rose 1.54% to $16,265.64, after two successive sessions in a row of losses, on what was an all-around bullish trend exchanging session today.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.86%.
Volume
Today’s last reported volume for HighPeak Energy is 208 which is 94.77% below its average volume of 3981.
Moving Average
HighPeak Energy’s worth is way higher than its 50-day moving average of $8.08 and above its 200-day moving average of $8.16.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.8%, now sitting on 1.11B for the twelve trailing months.
More news about HighPeak Energy.
8. Genprex (GNPX) – 10.59%
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
NASDAQ ended the session with Genprex jumping 10.59% to $4.70 on Tuesday while NASDAQ jumped 1.54% to $16,265.64.
Earnings Per Share
As for profitability, Genprex has a trailing twelve months EPS of $-24.4.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -158.09%.
More news about Genprex.
9. FibroGen (FGEN) – 10.53%
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
NASDAQ ended the session with FibroGen jumping 10.53% to $1.89 on Tuesday, following the last session’s downward trend. NASDAQ rose 1.54% to $16,265.64, after two consecutive sessions in a row of losses, on what was an all-around up trend trading session today.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-2.92.
Earnings Before Interest, Taxes, Depreciation, and Amortization
FibroGen’s EBITDA is 0.64.
Volatility
FibroGen’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.21%, a negative 2.49%, and a positive 8.38%.
FibroGen’s highest amplitude of average volatility was 2.65% (last week), 7.32% (last month), and 8.38% (last quarter).
More news about FibroGen.
10. Greenland Technologies Holding Corporation (GTEC) – 10.36%
Greenland Technologies Holding Corporation, through its subsidiaries, develops and manufactures transmission and drivetrain systems for material handling machineries and electric vehicles, and electric industrial vehicles in the People's Republic of China and internationally. The company offers transmission products for forklift trucks that are used in manufacturing and logistic applications, such as factories, workshops, warehouses, fulfillment centers, shipyards, and seaports. It also develops robotic cargo carriers. The company was founded in 2006 and is based in Hangzhou, the People's Republic of China.
NASDAQ ended the session with Greenland Technologies Holding Corporation jumping 10.36% to $2.77 on Tuesday, following the last session’s downward trend. NASDAQ rose 1.54% to $16,265.64, after two sequential sessions in a row of losses, on what was an all-around bullish trend exchanging session today.
Earnings Per Share
As for profitability, Greenland Technologies Holding Corporation has a trailing twelve months EPS of $0.13.
PE Ratio
Greenland Technologies Holding Corporation has a trailing twelve months price to earnings ratio of 21.31. Meaning, the purchaser of the share is investing $21.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.71%.
Volume
Today’s last reported volume for Greenland Technologies Holding Corporation is 3515 which is 91.78% below its average volume of 42813.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Greenland Technologies Holding Corporation’s EBITDA is 34.55.
More news about Greenland Technologies Holding Corporation.
Losers Today
1. Hycroft Mining Holding Corporation (HYMCW) – -20.47%
Hycroft Mining Holding Corporation, together with its subsidiaries, operates as a gold and silver producer in the United States. The company holds interests in the Hycroft mine covering an area of approximately 70,671 acres located in the state of Nevada. As of December 31, 2020, its Hycroft mine had proven and probable mineral reserves of 11.9 million ounces of gold, and 478.5 million ounces of silver. Hycroft Mining Holding Corporation was formerly known as Mudrick Capital Acquisition Corporation. The company was incorporated in 2017 and is based in Denver, Colorado.
NASDAQ ended the session with Hycroft Mining Holding Corporation dropping 20.47% to $0.01 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ rose 1.54% to $16,265.64, after two consecutive sessions in a row of losses, on what was an all-around bullish trend trading session today.
Earnings Per Share
As for profitability, Hycroft Mining Holding Corporation has a trailing twelve months EPS of $-1.543.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -116.41%.
Yearly Top and Bottom Value
Hycroft Mining Holding Corporation’s stock is valued at $0.01 at 17:32 EST, way below its 52-week low of $0.01.
More news about Hycroft Mining Holding Corporation.
2. Identiv (INVE) – -17.5%
Identiv, Inc. operates as a security technology company that secures things, data, and physical places in the Americas, Europe, the Middle East, and the Asia-Pacific. The company operates in two segments, Identity and Premises. The Identity segment offers products and solutions that enables secure access to information serving the logical access and cyber security markets, as well as protecting connected objects and information using radio-frequency identification embedded security. The Premises segment provides solutions for premises security market, such as access control, video surveillance, analytics, audio, access readers, and identities to government facilities, schools, utilities, hospitals, stores, and apartment buildings. The company sells its products through dealers, systems integrators, value added resellers, and resellers. The company was formerly known as Identive Group, Inc. and changed its name to Identiv, Inc. in May 2014. Identiv, Inc. was founded in 1990 and is headquartered in Fremont, California.
NASDAQ ended the session with Identiv dropping 17.5% to $7.12 on Tuesday, following the last session’s upward trend. NASDAQ rose 1.54% to $16,265.64, after two consecutive sessions in a row of losses, on what was an all-around bullish trend exchanging session today.
Earnings Per Share
As for profitability, Identiv has a trailing twelve months EPS of $-0.21.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.77%.
More news about Identiv.
3. Southwest Airlines (LUV) – -14.86%
Southwest Airlines Co. operates as a passenger airline company that provides scheduled air transportation services in the United States and near-international markets. As of December 31, 2023, the company operated a total fleet of 817 Boeing 737 aircraft; and served 121 destinations in 42 states, the District of Columbia, and the Commonwealth of Puerto Rico, as well as ten near-international countries, including Mexico, Jamaica, the Bahamas, Aruba, the Dominican Republic, Costa Rica, Belize, Cuba, the Cayman Islands, and Turks and Caicos. It also provides inflight entertainment and connectivity services on Wi-Fi enabled aircraft; and Rapid Rewards loyalty program that enables program members to earn points for dollars spent on Southwest base fares. In addition, the company offers a suite of digital platforms to support customers' travel needs, including websites and apps; and SWABIZ, an online booking tool. Further, it provides ancillary services, such as Southwest's EarlyBird Check-In, upgraded boarding, and transportation of pets and unaccompanied minors. Southwest Airlines Co. was incorporated in 1967 and is headquartered in Dallas, Texas.
NYSE ended the session with Southwest Airlines dropping 14.86% to $28.76 on Tuesday while NYSE jumped 0.62% to $17,974.06.
Earnings Per Share
As for profitability, Southwest Airlines has a trailing twelve months EPS of $0.76.
PE Ratio
Southwest Airlines has a trailing twelve months price to earnings ratio of 37.84. Meaning, the purchaser of the share is investing $37.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.39%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 70.4% and a drop 23.9% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Southwest Airlines’s stock is considered to be overbought (>=80).
Sales Growth
Southwest Airlines’s sales growth is 13.3% for the ongoing quarter and 8.4% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Mar 5, 2024, the estimated forward annual dividend rate is 0.72 and the estimated forward annual dividend yield is 2.1%.
More news about Southwest Airlines.
4. Funko (FNKO) – -9.48%
Funko, Inc., a pop culture consumer products company, designs, sources, and distributes licensed pop culture products in the United States, Europe, and internationally. The company offers vinyl, blind-packed miniature, and action figures; plush products; accessories; apparels, such as t-shirts and hats; homewares, including drinkware, party lights and other home accessories, such as keychains, pens, and pins; and bags, purses and wallets, and board games. It offers its products under the Pop!, Loungefly, Mystery Minis, Paka Paka, Funko Soda, and Snapsies brand names; and licenses its properties under the classic evergreen, movie release, current TV, and current video game categories. The company sells its products to specialty retailers, mass-market retailers, e-commerce sites, and distributors; and at specialty licensing and comic book shows, conventions, and exhibitions, as well as through its e-commerce business. Funko, Inc. was incorporated in 2017 and is headquartered in Everett, Washington.
NASDAQ ended the session with Funko falling 9.48% to $6.21 on Tuesday, following the last session’s downward trend. NASDAQ jumped 1.54% to $16,265.64, after two sequential sessions in a row of losses, on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, Funko has a trailing twelve months EPS of $-3.19.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -52.39%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 12.6%, now sitting on 1.1B for the twelve trailing months.
Sales Growth
Funko’s sales growth for the current quarter is negative 8.3%.
Moving Average
Funko’s worth is way below its 50-day moving average of $7.24 and way below its 200-day moving average of $7.92.
More news about Funko.
5. Gritstone Oncology (GRTS) – -9.06%
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.
NASDAQ ended the session with Gritstone Oncology falling 9.06% to $2.41 on Tuesday, following the last session’s downward trend. NASDAQ rose 1.54% to $16,265.64, after two consecutive sessions in a row of losses, on what was an all-around bullish trend exchanging session today.
Earnings Per Share
As for profitability, Gritstone Oncology has a trailing twelve months EPS of $-1.2.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -124.41%.
Volume
Today’s last reported volume for Gritstone Oncology is 1597750 which is 25.55% below its average volume of 2146150.
Revenue Growth
Year-on-year quarterly revenue growth grew by 143.6%, now sitting on 16.34M for the twelve trailing months.
Yearly Top and Bottom Value
Gritstone Oncology’s stock is valued at $2.41 at 17:32 EST, way under its 52-week high of $3.33 and way above its 52-week low of $1.14.
More news about Gritstone Oncology.
6. Pacific Biosciences of California (PACB) – -8.86%
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
NASDAQ ended the session with Pacific Biosciences of California dropping 8.86% to $4.01 on Tuesday, after three sequential sessions in a row of losses. NASDAQ jumped 1.54% to $16,265.64, after two sequential sessions in a row of losses, on what was an all-around up trend trading session today.
Earnings Per Share
As for profitability, Pacific Biosciences of California has a trailing twelve months EPS of $-1.21.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.53%.
More news about Pacific Biosciences of California.
7. iRobot (IRBT) – -7.85%
iRobot Corporation designs, builds, and sells robots and home innovation products in the United States, Europe, the Middle East, Africa, Japan, and internationally. The company offers floor care products, including Roomba floor vacuuming robots; Roomba accessories and consumables, such as the Clean Base Automatic Dirt Disposal, replacement dirt disposal bags for the Clean Base, filters, brushes, and batteries; Braava family of automatic floor mopping robots; and Braava accessories and consumables, which include cleaning solution, washable and disposable mopping pads, replacement tanks, and batteries, as well as subscription services. It also provides Root robots for coding, discovery, and play; Roomba Combo mopping and vacuuming robot; and accessories, including robot vacuum and mop, handheld vacuum, and air purifier, educational coding robot, and accessory bundles. The company sells its products through chain stores and other national retailers, value- added distributors, and resellers, as well as through its website and app, and e-commerce websites. iRobot Corporation was incorporated in 1990 and is headquartered in Bedford, Massachusetts.
NASDAQ ended the session with iRobot falling 7.85% to $9.86 on Tuesday while NASDAQ jumped 1.54% to $16,265.64.
Irobot (irbt) provides Q1 fy24 outlook, restates fy24 viewFor 2024, iRobot expects revenues in the range of $825-$865 million, indicating a year-over-year decrease of 5.2%.
Earnings Per Share
As for profitability, iRobot has a trailing twelve months EPS of $-11.01.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4%.
Volatility
iRobot’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.68%, a negative 1.41%, and a positive 3.78%.
iRobot’s highest amplitude of average volatility was 0.68% (last week), 2.29% (last month), and 3.78% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, iRobot’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for iRobot is 2793270 which is 5.96% above its average volume of 2635970.
Sales Growth
iRobot’s sales growth is negative 1% for the current quarter and negative 29.9% for the next.
More news about iRobot.
8. Forte Biosciences (FBRX) – -6.96%
Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California.
NASDAQ ended the session with Forte Biosciences falling 6.96% to $0.71 on Tuesday while NASDAQ jumped 1.54% to $16,265.64.
Earnings Per Share
As for profitability, Forte Biosciences has a trailing twelve months EPS of $-1.2.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -73.23%.
Yearly Top and Bottom Value
Forte Biosciences ‘s stock is valued at $0.71 at 17:32 EST, way under its 52-week high of $1.29 and way above its 52-week low of $0.38.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Forte Biosciences ‘s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for Forte Biosciences is 37989 which is 7.76% below its average volume of 41185.
More news about Forte Biosciences .
9. Future FinTech Group (FTFT) – -6.6%
Future FinTech Group Inc., through its subsidiaries, operates a real-name block chain e-commerce platform that integrates block chain and internet technology in People's Republic of China. It operates through CCM Shopping Mall Membership, Sales of Goods, and Others segments. The company offers Chain Cloud Mall (CCM), an enterprise customer interactive and comprehensive shopping and sales service platform; NONOGIRL, a cross-border e-commerce platform; and DCON, a block chain-based application incubator and a digital payment system. It also engages in the development of block chain-based e-commerce and financial technology; and provides technical services and support for real name and blockchain based assets. The company was formerly known as SkyPeople Fruit Juice, Inc. and changed its name to Future FinTech Group Inc. in June 2017. Future FinTech Group Inc. is headquartered in Beijing, the People's Republic of China.
NASDAQ ended the session with Future FinTech Group sliding 6.6% to $0.96 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ jumped 1.54% to $16,265.64, after two consecutive sessions in a row of losses, on what was an all-around up trend exchanging session today.
Earnings Per Share
As for profitability, Future FinTech Group has a trailing twelve months EPS of $-0.8.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.54%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 98.6%, now sitting on 31.99M for the twelve trailing months.
Volume
Today’s last reported volume for Future FinTech Group is 88882 which is 48.11% below its average volume of 171308.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Future FinTech Group’s EBITDA is 5.87.
More news about Future FinTech Group.
10. Xenetic Biosciences (XBIO) – -6.54%
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
NASDAQ ended the session with Xenetic Biosciences dropping 6.54% to $4.00 on Tuesday, after three sequential sessions in a row of gains. NASDAQ rose 1.54% to $16,265.64, after two consecutive sessions in a row of losses, on what was an all-around up trend exchanging session today.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-2.9.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.98%.
More news about Xenetic Biosciences.
Stay up to date with our winners and losers daily report
